Clinical information | N (%) / Median [IQR] |
---|---|
Age [years] | 53[5.5] |
Male gender | 8(72.7) |
Tumor stage | |
I | 1(9.1) |
II | 1(9.1) |
III | 4(36.4) |
IV | 5(45.5) |
Tumor depth | |
T1 | 1(9.1) |
T2 | 1(9.1) |
T3 | 3(27.3) |
T4 | 6(54.5) |
Tumor locations | |
ileocecal | 1(9.1) |
Ascending colon | 2(18.2) |
Transverse colon | 1(9.1) |
Descending colon | 1(9.1) |
Sigmoid colon | 2(18.2) |
Rectum | 3(27.3) |
Multi-site (sigmoid colon + cecum) | 1(9.1) |
Ki-67 (%) | 40% [15.5%] |
Tumor diameter (cm) | 6.0 [3.5] |
Metastatic sites | |
Lung | 1(9.1) |
Liver | 1(9.1) |
Peritoneal | 2(18.2) |
Ureter | 1(9.1) |
Lymph node | 7(63.6) |
Neoadjuvant therapy | 1(9.1) |
Adjuvant therapy | |
Chemotherapy | 3(27.3) |
Immunotherapy | 1(9.1) |
Radiotherapy | 1(9.1) |
Tumor progression | 7(63.6) |
Local recurrence | 4(36.4) |
Distant metastasis | Â |
Liver | 1(9.1) |
Ureter | 1(9.1) |